**What is already known about the topic?** •Masks and respirators are commonly used to protect from respiratory infections in three different indications -- for healthcare workers, sick patients and well community members.•Currently there is debate and conflicting guidelines around the use of masks and respirators in healthcare and community settings.

**What this paper adds** •In the community, masks may be more protective for well people.•In healthcare settings continuous use of respirators, is more protective compared to the medical masks, and medical masks are more protective than cloth masks. Depending on the fabric and design, some cloth masks may not be safe for healthcare workers.•The use of masks by sick patients is likely protective, and coronaviruses can be emitted in normal breathing, in fine airborne particles.

1. Introduction {#sec0001}
===============

The use of personal protective equipment for coronavirus disease (COVID-19) has been controversial, with differing guidelines issued by different agencies ([@bib0001]). COVID-19 is caused by severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), a beta-coronavirus, similar to severe acute respiratory syndrome coronavirus (SARS CoV) ([@bib0001]). Seasonal alpha and beta coronaviruses cause common colds, croup and broncholitis. The transmission mode of coronaviruses in humans is similar, thought to be by droplet, contact and sometimes airborne routes ([@bib0002]; [@bib0003]; [@bib0004]). The World Health Organization recommends surgical mask for health workers providing routine care to a coronavirus disease patient ([@bib0005]), whilst the US Centers for Disease Control and Prevention recommended a respirator ([@bib0006]). Most authorities, except the US CDC, are recommending that community members not wear a mask, and that a mask should only be worn by a sick patient (also referred to as *source control*) ([@bib0007]). There are more randomised controlled trials of community use of masks in well people than studies of the use by sick people (*source control*). The aim of this study was to review the randomised controlled trials evidence for use of masks and respirators by the community, health care workers and sick patients for prevention of infection.

2. Methods {#sec0002}
==========

We searched Medline and EmBase for clinical trials on masks and respirators using the key words "mask", "respirator", and "personal protective equipment". The search was conducted between 1 March to April 17 2020, and all randomised controlled trials published before the search date were included. Two authors (CRM and AAC) reviewed the title and abstracts to identify randomised controlled trials on masks and respirators. We also searched relevant papers from the reference lists of previous clinical trials and systematic reviews. Studies that were not randomised controlled trials, were about anesthesia, or not about prevention of infection were excluded. Animal studies, experimental and observational epidemiologic studies were also excluded. Studies published in English language were included.

We found 602 papers on Medline and 250 on Embase. 820 papers were excluded by title and abstract review. Full texts were reviewed for 32 papers and 19 were selected in this review. Results were reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) criteria ([@bib0008]).

3. Results {#sec0003}
==========

In general, the results show protection for healthcare workers and community members, and likely benefit of masks used as source control. We found eight clinical trials ([@bib0009]; [@bib0010]; [@bib0011]; [@bib0012]; [@bib0016]; [@bib0014], [@bib0015]; [@bib0016]) on the use of masks in the community ([Table 1](#tbl0001){ref-type="table"} ). In the community, masks appear to be effective with and without hand hygiene, and both together are more protective ([@bib0009]; [@bib0012]; MacIntyre et al., 2009). However, some randomised controlled trials which measured both hand hygiene and masks measured the effect of hand hygiene alone, but not of masks alone ([@bib0010], [@bib0016]). In more than one trial, interventions had to be used within 36 hours of exposure to be effective ([@bib0016]; [@bib0015]).Table 1Community mask trials.Table 1Author, yearN, countryInterventionsResults[@bib0014]198 Households\
Hong KongMedical masks\
Hand washing\
ControlNS -- this was a preliminary report of the 2009 trial.[@bib0013]143 Households\
AustraliaMedical masks\
P2 masks\
ControlIntention to treat non-significant. Adherence with mask wearing low (25-30% by day 5). In sub-analysis, masks/P2 protective if adherent.[@bib0016])407 households\
Hong KongHand hygiene\
Masks + hand hygiene\
ControlIntention to treat not significant. Masks plus hand hygiene protective against lab confirmed influenza if used within 36 hours. Hand hygiene alone not significant.[@bib0012])1437 college students, United States of AmericaMasks Masks + hand washing\
ControlIntention to treat non-significant. Masks + handwashing protective in week 4 -6 of observation and beyond.[@bib0009])1178 college students, United States of AmericaMasks\
Masks + hand hygiene\
ControlIntention to treat non-significant. Masks + hand hygiene protective in week 3 of observation and beyond. Masks alone not protective.[@bib0011])617 households, United States of AmericaHealth education (HE)\
Hand hygiene + HE\
Masks + hand hygiene +HEMasks + hand hygiene + HE protective against secondary transmission measured by confirmed influenza and ILI. Mean secondary attack rates for HE, HE + HH, HE+HH+M groups were 0.023, 0.020, and 0.018, respectively[@bib0010])465 index patients and their families, ThailandHand hygiene\
Masks + hand hygiene\
ControlNo significant difference in confirmed influenza infection[@bib0015]84 index cases and 218 household contacts, GermanyMasks\
Masks + hand hygiene\
ControlIntention to treat analysis was non-significant. Where used within 36 h, secondary infection in the pooled M and MH groups was significantly lower compared to the control group. In multivariable analysis for predictors of qRT-PCR confirmed influenza infection and clinical influenza among included households in separate models allowing for within household correlation, M and MH were protective against Influenza AH1N1pdm09.

To date, six randomised controlled trials ([@bib0017]; [@bib0018], [@bib0022], [@bib0020], [@bib0019], [@bib0021] ) have been conducted on the use of masks and/or respirators by healthcare workers in health care settings ([Table 2](#tbl0002){ref-type="table"} ). The healthcare worker trials ([Table 2](#tbl0002){ref-type="table"}) used different interventions and different outcome measures, and one was in the outpatient setting. A Japanese study had only 32 subjects, and likely was underpowered to find any difference between masks and control ([@bib0018]). Two North American trials of masks and respirators against influenza infection found no difference between the arms, but neither had a control arm to differentiate equal efficacy from equal inefficacy ([@bib0017], [@bib0022]). Neither trial can prove equivalence, as this requires one intervention to be already proven efficaceous against placebo. Without a control group to determine rates of influenza in unprotected healthcare workers, neither study is able to determine efficacy if no difference was observed between the two interventions. A serologic study showed that up to 23% of unprotected healthcare workers (a rate identical to that observed in Loeb the trial, which also used serology) contract influenza during outbreaks ([@bib0023]), which suggests lack of efficacy. Studies of nosocomial influenza generally find lower influenza attack rates in unprotected healthcare workers than observed in the Loeb trial ([@bib0024]).Table 2Trials of mask and respirator use by health care workers.Table 2Author, yearN healthcare workers, CountryInterventionsResults[@bib0018]32\
JapanMedical masks\
ControlNS[@bib0022]446\
CanadaMedical masks, targeted N95No significant difference between Masks and targeted N95[@bib0020]1441\
ChinaMasks\
N95 respirators, fit tested\
N95 respirators, non-fit tested\
ControlContinuous N95 protective against clinical, viral and bacterial endpoints[@bib0019]1669\
ChinaMedical Mask\
N95 (continuous)\
N95 (targeted)Continuous N95 protective\
No difference between targeted N95 and medical masks[@bib0021]1607\
VietnamMedical masks, cloth masks, controlMedical masks protective or Cloth masks increase risk of infection[@bib0017])2862\
United States of AmericaMedical masks, targeted\
N95 (when 2 m from confirmed respiratory infection) in Outpatient setting.No significant difference between\
Masks and targeted N95

Further problems with this study are that the majority of subjects were defined as having influenza on the basis of serological positivity ([@bib0022]). The 10% seroconversion to pandemic H1N109 (with no pandemic virus isolation or positive PCR) observed in the trial, suggests that pandemic H1N109 was circulating in Ontario before April 2009, which is unlikely.

A serological definition of influenza can be affected by vaccination. The authors claim they excluded influenza vaccinated subjects in the outcome, but according to figure 1 in the Loeb trial, ([@bib0022]) these subjects (130 in total) are included in the analysis. If they had been excluded and even if no other subjects were excluded, the total analysed would be 348, which is lower than the 422 subjects analysed ([@bib0022]). These 130 vaccinated subjects should have been excluded entirely from the analysis. The vaccination status of subjects with seropositivity is not provided in the paper, but it appears people with positive serology due to vaccination may have been misclassified as influenza cases ([@bib0022]).Fig. 1Search strategy and selection of papers.Fig 1

In both the North American trials, the intervention comprised wearing the mask or respirator when in contact with recognized ILI or when doing a high risk procedure, which is a targeted strategy ([@bib0017], [@bib0022]). One was in an outpatient setting. ([@bib0017]) We conducted a randomised controlled trial comparing the targeted strategy tested in the two North American studies, with the wearing of respiratory protection during an entire shift, and showed efficacy for continual (but not targeted) use of a respirator ([@bib0019]). The study also did not show efficacy for a surgical mask worn continually, and therefore no difference between a surgical mask and targeted use of a respirator ([@bib0019]), which is consistent with the findings of the North American trials ([@bib0017], [@bib0022]). In summary, the evidence is consistent that a respirator must be worn throughout the shift to be protective. Targeted use of respirators only when doing high risk procedures and medical mask use is not protective. Another randomised controlled trial we conducted in China showed efficacy for continual use of a respirator, but not for a mask, and also found fit-testing of the respirator did not affect efficacy ([@bib0020]). However, this may be specific to the quality of the tested product, and is not generalisable to other respirators -- fit testing is a necessary part of respirator use ([@bib0025]).

For healthcare workers, there is evidence of efficacy of respirators if worn continually during a shift, but no evidence of efficacy of a mask ([@bib0020], [@bib0019]). For hospitals where COVID-19 patients are being treated, there is growing evidence of widespread contamination of the ward environment, well beyond 2 m from the patient, as well as aerosol transmission ([@bib0002]; [@bib0026]; [@bib0027]). Several studies have found SARS-CoV-2 on air vents and in air samples in intensive care units and COVID-19 wards ([@bib0026]; [@bib0028]; [@bib0029]), and an experimental study showed the virus in air samples three hours after aerosolization ([@bib0030]). The weight of this evidence and the precautionary principle ([@bib0031]a; [@bib0032]b), favors respirators for healthcare workers. We showed lower rates of infection outcomes in the medical mask arm compared to control, but the difference was not significant ([@bib0020]). It could be that larger trials are needed to demonstrate efficacy of a mask, but any protection is far less than from a respirator. A trial we conducted in Vietnam of 2-layered cotton cloth masks compared to medical masks showed a lower rate of infection in the medical mask group, and a 13 times higher risk of infection in the cloth mask arm ([@bib0021]). The study suggests cloth masks may increase the risk of infection ([@bib0021]), but may not be generalizable to all homemade masks. The material, design and adequacy of washing of cloth masks may have been a factor ([@bib0033]). There are no other randomised controlled trial of cloth masks published at this time, but if any protection is offered by these it would be less than even a medical mask.

[Table 3](#tbl0003){ref-type="table"} shows the trials of source control. There were five randomised controlled trials identified of masks used by sick patients ([@bib0034], [@bib0037], [@bib0038], [@bib0035], [@bib0036]). One was an experimental study of 9 influenza patients, which did not measure clinical endpoints ([@bib0034]). Participants with confirmed influenza coughed onto culture medium wearing a N95 respirator or a mask. No influenza grew on the medium. A trial of 105 sick patients wearing a mask (or no mask) in the household found no significant difference between arms ([@bib0036]). However, the trial was terminated prematurely and did not meet recruitment targets, so was probably underpowered. One randomised controlled trial was conducted among Hajj pilgrims, with both well and sick pilgrims wearing masks, and low rates of ILI were reported among contact of mask pilgrims ([@bib0037]). Our randomised controlled trial is the largest available with clinical endpoints, and studied 245 patients randomised to mask or control ([@bib0035]). Compliance was suboptimal in the mask group and some controls wore masks. The intention to treat analysis showed no difference, but when analysed by actual mask use, the rate of infection in household contacts was lower in those who wore masks ([@bib0035]). A trial with an experimental design was published in April 2020, examining a range of viruses including seasonal human coronaviruses ([@bib0038]). This showed that coronaviruses are preferentially found in aerosolized particles compared to large droplets, and could be expelled by normal tidal breathing. Wearing a surgical mask prevented virus from being exhaled.Table 3Trials of Masks used by a sick patient as source control.Table 3Author, year*N*, countryInterventionsResults[@bib0034])9 subjects with confirmed influenza, AustraliaMedical mask\
N95 (participants coughed 5 times onto a Petri dish wearing each device)NS - Surgical and N95 masks were equally effective in preventing the spread of PCR-detectable influenza[@bib0036]105 index cases and 306 household contacts, FranceMedical mask\
ControlNo significant difference, but trial terminated early[@bib0035]245 index cases and 597 household contacts,Medical mask worn by sick case\
Control (no mask) Household contacts\
Followed for infection.Intention to treat analysis not significant. Mask protective if worn[@bib0037]Hajj Setting. 22 tents were randomised to 'mask' (*n* = 12) or 'control' (*n* = 10)\
75 pilgrims in 'mask' and 89 in 'control' group\
Saudi ArabiaMask and controlLess ILI among the contacts of mask users compared to the control tents (31% versus 53%, *p* = 0.04).\
Laboratory results did not show any difference between the two groups[@bib0038])Experimental study of 246 subjects randomised to surgical mask and no maskMask and control111 were infected by human (seasonal) coronavirus. Coronavirus found in exhaled breath of no-mask subjects but not in mask wearers. More virus was found in fine aerosols than large droplets

4. Discussion {#sec0004}
=============

There are more randomised controlled trials of community use of masks in well people ([@bib0009]; [@bib0010]; [@bib0011]; [@bib0012]; [@bib0013]; [@bib0014], [@bib0015], [@bib0016]) than studies of the use by sick people (also referred to as "*source control"*), and these trials are larger than the few on source control ([@bib0034], [@bib0038], [@bib0035]). The evidence suggests protection by masks in high transmission settings such as household and college settings, especially if used early, in some trials if combined with hand hygiene and if wearers are compliant ([@bib0009]; [@bib0012]; [@bib0013]; [@bib0014], [@bib0016], [@bib0015]). If masks protect in high transmission settings, they should also protect in crowded public spaces, including workplaces, buses, trains, planes and other closed settings. The trial which did not show efficacy used influenza as the outcome measure ([@bib0010]), which is a rare outcome, so requires a larger sample size for adequate power and may have been underpowered.

For healthcare workers, the only trials to show a difference between respirators and masks demonstrated efficacy for continuous use of a respirator through a clinical shift, but not masks ([@bib0020], [@bib0019]). The two trials which showed no difference are widely cited as evidence that masks provide equal protection as respirators ([@bib0017], [@bib0022]). However, without a control arm, the absence of difference between arms could reflect equal efficacy or inefficacy, and it is not possible to draw any conclusions about efficacy. The outpatient setting in the US trial may have had lower exposure risk than the inpatient setting of other trials. ([@bib0017]) In both the North American trials, the intervention comprised wearing the mask or respirator intermittently when in contact with recognized ILI or when doing a high risk procedure ([@bib0017], [@bib0022]). The underlying assumption that the majority of infections in healthcare workers occur during self-identified high-risk exposures is not supported by any evidence. It assumes healthcare workers can accurately identify when they are risk in a busy, clinical setting, when the majority of infections may occur when healthcare workers are unaware of the risk (such as when walking through a busy emergency room or ward where aerosolized virus may be present). Conversely, infections could occur outside the workplace. This could explain the lack of difference if there was no actual efficacy of either arm and if much of the infection occurs in unrecognized situations of risk either within or outside the workplace.

In practice, hospital infection control divides infections into droplet or airborne spread, and recommends droplet (mask) or airborne (respirator) precautions accordingly ([@bib0039]). In a pooled analysis of both healthcare worker trials, we showed that continual use of a respirator is more efficacious in protecting healthcare workers even against infections assumed to be spread by the droplet route ([@bib0039]). Medical masks did not significantly protect against viral, bacterial, droplet or other infection outcomes. However, the summary odds ratio for masks was less than one, which suggests a low level of protection. Targeted use of respirator protected against bacterial and droplet infections, but not against viral infections, suggesting viral infections may be more likely to be airborne in the hospital setting ([@bib0039]).

The five available studies of mask use by sick patients suggest a benefit, but are much smaller trials than the community trials, two without clinical endpoints, and with less certainty around the findings ([@bib0034], [@bib0037], [@bib0038], [@bib0035], [@bib0036]). Only 3/5 trials examined clinical outcomes in close contacts ([@bib0037], [@bib0035], [@bib0036]) and suggest a benefit

Many systematic reviews have been conducted on masks, respirators and other PPE in past ([@bib0040]; [@bib0041]; [@bib0042]; [@bib0043]; [@bib0044]; [@bib0045]; [@bib0046]; [@bib0047]; [@bib0048]; [@bib0049]). These reviews generally examined multiple interventions (e.g. masks and hand hygiene etc.), often combined different outcome measures that were not directly comparable and were inconclusive. Moreover, most of these reviews did not include more recent randomised controlled trials ([@bib0017], [@bib0021]). This systematic review only focuses on masks and respirators and contains all new studies.

In summary, there is a growing body of evidence supporting all three indications for respiratory protection -- community, healthcare workers and sick patients (source control). The largest number of randomised controlled trials have been done for community use of masks by well people in high-transmission settings such as household or college settings. There is benefit in the community if used early, with hand hygiene and if compliant.

Respirators protect healthcare workers if worn continually, but not if worn intermittently in self-identified situations of risk. This supports the suggestion that the health care environment is a risk to healthcare workers even when not doing aerosol generating procedures or caring for a known infectious patient. For COVID-19 specifically, the growing body of evidence showing aerosolisation of the virus in the hospital ward highlights the risk of inadvertent exposure for healthcare workers and supports the use of airborne precautions at all times on the ward ([@bib0026]; [@bib0028]; [@bib0029]). Further, the rule of 1--2 m of spatial separation is not based on good evidence, with most research showing that droplets can travel further than 2 m, and that infections cannot be neatly separated into droplet and airborne ([@bib0039]; [@bib0050]). In the UK, one healthcare trust found almost one in five healthcare workers to be infected with COVID-19 ([@bib0051]). The deaths of healthcare workers from COVID-19 reflect this risk ([@bib0052]). The use of masks by sick people, despite being the WHO\'s only recommendation for mask use by community members during COVID-19 pandemic, is supported by the smallest body of evidence. Source control is probably a sensible recommendation given the suggestion of protection and given specific data on coronaviruses showing protection ([@bib0038]). It may help if visitors and febrile patients wear a mask in the healthcare setting, whether in primary care or hospitals. Universal face mask use is likely to have the most impact on epidemic growth in the community, given the high risk of asymptomatic and pre-symptomatic transmission ([@bib0053]).
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